Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vismodegib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 33,551Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vismodegib hard capsule 150 mg product-specific bioequivalence guidance
    Vismodegib hard capsule 150 mg product-specific bioequivalence guidance

    03 Aug 2018

    // EMA

    http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/08/WC500252981.pdf

    EMA
    03 Aug 2018
    Share Share
    AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures
    AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures

    26 Jul 2018

    // Ben Adams FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/astrazeneca-s-selumetinib-flops-thyroid-cancer-adding-to-list-failures?utm_source=internal&utm_medium=rss

    Ben Adams FIERCE BIOTECH
    26 Jul 2018
    Share Share
    Roche’s skin cancer drug Erivedge pulled from CDF
    Roche’s skin cancer drug Erivedge pulled from CDF

    13 Oct 2017

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/roches_skin_cancer_drug_erivedge_pulled_from_cdf_1208231

    Selina McKee PHARMA TIMES
    13 Oct 2017
    Share Share
    How Top Indian Drug Makers Like Sun, Glenmark are Building Business in the US
    How Top Indian Drug Makers Like Sun, Glenmark are Building Business in the US

    07 Jan 2017

    // Vikas Dandekar ECONOMIC TIMES

    http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/how-top-indian-drug-makers-like-sun-pharma-glenmark-are-building-a-brands-business-in-the-us/articleshow/56382828.cms

    Vikas Dandekar ECONOMIC TIMES
    07 Jan 2017
    Share Share
    Curis Announces Full Approval of Roche’s Erivedge® in the European Union
    Curis Announces Full Approval of Roche’s Erivedge® in the European Union

    28 Nov 2016

    // GLOBENEWSWIRE

    https://globenewswire.com/news-release/2016/11/28/893036/0/en/Curis-Announces-Full-Approval-of-Roche-s-Erivedge-in-the-European-Union.html

    GLOBENEWSWIRE
    28 Nov 2016
    Share Share